RxDoctor Payments Data

Chloe Braamse, NP

Family · Carlsbad, CANPI 1790413367

Payments from drug & device makers

$676in general payments, 2019–2025

Across 29 payments — averaging $23.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$206
  • Lilly USA, LLC$73
  • AbbVie$69
  • Inspire Medical Systems, Inc.$47
  • Exact Sciences$47
  • Organon$36
  • plus $197 from 10 others

What the payments were for

  • Food & beverage$676100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$676 in reported general payments places this provider in the 65th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$5,505
Medicare patients
29
Services billed
64

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin20$26,103
OzempicSemaglutide25$23,792
MounjaroTirzepatide12$11,867
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,598
Atorvastatin Calcium75$1,078
Levothyroxine Sodium69$867
Celecoxib22$643
Albuterol Sulfate HfaAlbuterol Sulfate20$497
Gabapentin24$488
Diclofenac Sodium18$459
Fluticasone Propionate52$444
Metformin Hcl50$411
Tamsulosin Hcl34$406
Omeprazole37$323
Losartan Potassium28$317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$13$23,79225 claims
Lilly USA, LLCMounjaro$73$11,86712 claims
AstraZenecaBreztri Aerosphere$206$7,59812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,634 family providers in California.

Other family in Carlsbad

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →